McGrath Emer R, Go Alan S, Chang Yuchiao, Borowsky Leila H, Fang Margaret C, Reynolds Kristi, Singer Daniel E
Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts.
Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts.
J Am Geriatr Soc. 2017 Feb;65(2):241-248. doi: 10.1111/jgs.14688. Epub 2016 Dec 30.
To explore barriers to anticoagulation in older adults with atrial fibrillation (AF) at high risk of stroke and to identify opportunities for interventions that might increase use of oral anticoagulants (OACs).
Retrospective cohort study.
Two large community-based AF cohorts.
Individuals with ischemic stroke surviving hospitalization (N = 1,405, mean age 79).
Using structured chart review, reasons for nonuse of OAC were identified, and 1-year poststroke survival was assessed. Logistic regression was used to identify correlates of OAC nonuse.
Median CHA DS -VASc score was 5, yet 44% of participants were not prescribed an OAC at discharge. The most-frequent (nonmutually exclusive) physician reasons for not prescribing OAC included fall risk (26.7%), poor prognosis (19.3%), bleeding history (17.1%), participant or family refusal (14.9%), older age (11.0%), and dementia (9.4%). Older age (odds ratio (OR) = 8.96, 95% confidence interval (CI) = 5.01-16.04 for aged ≥85 vs <65) and disability (OR = 12.58, 95% CI = 5.82-27.21 for severe vs no deficit) were the most-important independent predictors of nonuse of OACs. By 1 year, 42.5% of those not receiving an OAC at discharge had died, versus 19.1% of those receiving an OAC (P < .001), far higher than recurrent stroke rates.
Despite very high stroke risk, more than 40% of participants were not discharged with an OAC. Dominant reasons included fall risk, poor prognosis, older age, and dementia. These individuals' high 1-year mortality rate confirmed their high level of comorbidity. To improve anticoagulation decisions and outcomes in this population, future research should focus on strategies to mitigate fall risk, improve assessment of risks and benefits of anticoagulation in individuals with AF, and determine whether newer anticoagulants are safer in complex elderly and frail individuals.
探讨高龄房颤(AF)且卒中风险高的患者接受抗凝治疗的障碍,并确定可能增加口服抗凝药(OAC)使用的干预机会。
回顾性队列研究。
两个大型社区房颤队列。
缺血性卒中住院幸存者(N = 1405,平均年龄79岁)。
通过结构化病历审查确定未使用OAC的原因,并评估卒中后1年生存率。采用逻辑回归确定未使用OAC的相关因素。
CHA₂DS₂-VASc评分中位数为5,但44%的参与者出院时未开具OAC。医生未开具OAC的最常见(非相互排斥)原因包括跌倒风险(26.7%)、预后不良(19.3%)、出血史(17.1%)、参与者或家属拒绝(14.9%)、高龄(11.0%)和痴呆(9.4%)。高龄(≥85岁与<65岁相比,优势比(OR)= 8.96,95%置信区间(CI)= 5.01 - 16.04)和残疾(严重残疾与无残疾相比,OR = 12.58,95%CI = 5.82 - 27.21)是未使用OAC的最重要独立预测因素。到1年时,出院时未接受OAC的患者中有42.5%死亡,而接受OAC的患者中这一比例为19.1%(P <.001),远高于复发性卒中发生率。
尽管卒中风险极高,但超过40%的参与者出院时未使用OAC。主要原因包括跌倒风险、预后不良、高龄和痴呆。这些个体1年的高死亡率证实了他们的高合并症水平。为改善该人群的抗凝决策和结果,未来研究应聚焦于降低跌倒风险的策略、改善房颤患者抗凝风险和获益评估,以及确定新型抗凝药在复杂老年和体弱个体中是否更安全。